CliffBio
small molecule

ZEJULA

NIRAPARIB TOSYLATE

Loss of exclusivityJanuary 2039latest FDA-listed patent expiry
CompanyGlaxoSmithKline →See this company's full patent-cliff portfolio

Drug detail

Brand nameZEJULA
Active ingredientNIRAPARIB TOSYLATE
StrengthEQ 200MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2023
Marketing statusRX

Listed patents

PatentExpiresType
11730725January 2039product
11673877March 2038product
11091459March 2038product
8859562August 2031use U-2655
8071623March 2031substance, product
8436185April 2029substance
8071579August 2027use U-2655
8143241August 2027use U-2655

More from GlaxoSmithKline

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ZEJULA patent cliff — loss of exclusivity January 2039 | CliffBio